Melanoma Perspective

 
 
  • Will PD-1 Agents Edge Out Interferon in Adjuvant Melanoma?   Dr Jeffrey Weber reviews the current options for adjuvant therapy in patients with resected melanoma and looks ahead to the use of PD-1 antibodies in this setting.
  • Essential Cancer Updates for Primary Care Physicians From cancer prevention to long-term survivorship, ASCO -- the most important cancer meeting of the year -- featured important practice updates for primary care physicians.
  • Vitamin D: A New Intervention for Melanoma?   Does the association of low vitamin D levels and poor outcomes in melanoma patients point to supplementation as a potential intervention for melanoma?
  • Counting Colorectal Tumors During Flights to Asia   After much retrospection and many transpacific airline flights, Dr Venook shares with Dr Kerr his research on sidedness of CRC and its effect on management of four apparent disease subtypes.
  • A 78-Year-Old Tennis Player With a Growth on His Scalp A 78-year-old man with Fitzpatrick skin type I presents with a growth on his scalp. What's your diagnosis?
  • The 'C' Word Whispered in Metastatic Melanoma   Is cure a possibility for some patients with metastatic melanoma? Dr Jeffrey Weber discusses long-term survival from the KEYNOTE-001 and COMBI-d studies, which show 'very impressive data indeed.'
  • #ASCO16: Hot Topics on Twitter Social media activity using #ASCO16 at the ASCO annual meeting achieved record-breaking highs in many categories.
  • Does Vismodegib for BCC Increase Risk for Subsequent SCCs? Dr Graeme Lipper reviews a new paper that evaluated the risk of developing a non-BCC malignancy after treatment with a smoothened inhibitor.
  • Which Cancer Patient Is a Candidate for Immunotherapy?   Because immunotherapies are approved for multiple cancers, Drs Weber and Postow discuss choosing the right patient for immunotherapy, taking into account comorbidities and potential adverse events.
  • Immunotherapy 'Plus': Adding Radiation and Chemo to Immune Therapies As data on single-agent immunotherapies mature, oncologists are beginning to turn their attention to combination approaches.
  • Cancer Moonshot: We Have Liftoff Initial reaction to the Moonshot ranged from cynicism to guarded optimism, but no one denies that momentum is building for this national cancer initiative -- and Big Data are the rocket boosters.
  • Trastuzumab Biosimilar: An Understudy Waits in the Wings   Drs Miller and Rugo talk about the trastuzumab biosimilar and what it could mean for patient care worldwide, the lessons from a failed vaccine study, and a practice change that can prevent stomatitis.
  • Findings From NEMO, and Other Melanoma Highlights   In a preview of ASCO melanoma studies, the NEMO results suggest that binimetinib is reasonable for NRAS-mutated melanoma, and combo regimens continue to show strong outcomes, reports Dr Jeffrey Weber.
  • Melanoma: ‘Tail’ on Survival Curve Is Getting Longer   Dr Jeffrey Weber, Medscape's new commentator on melanoma and immunotherapy, discusses impressive data on overall survival and combination therapy presented at AACR 2016.
  • From Bedside to Bench: A New Direction in Breast Cancer Research   Past AACR president Dr Carlos Arteaga describes translational studies and emerging therapies that are transforming the clinical practice of breast cancer.
  • Those Pesky Rashes and Lesions: Part 2   Put yourself to the test with Dr Charles Vega as Dr Graeme Lipper presents cases showcasing some common yet potentially confusing dermatologic conditions.
  • Society for Melanoma Research (SMR) 2015 Congress Read clinically focused news coverage of key developments from SMR 2015.
  • Systemic Options for Treating Brain Metastases The therapeutic challenge of brain metastases in lung cancer, breast cancer, and melanoma is being met by a growing number of systemic therapies, as highlighted in an integrated session of ECC 2015.
  • IPI Ousted as First-Line Immunotherapy in Melanoma? Dr Michael Atkins highlights the top melanoma findings from ASCO 2015, including impressive results for nivolumab, combination immunotherapies, and new strategies to target BRAF-mutant disease.
  • Melanoma 2014: Another Banner Year An avalanche of drugs and drug approvals, new combination therapies, and clear improvement in survival rates made 2014 an exciting year in melanoma, as highlighted by Dr Antoni Ribas.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.